Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice

5 Sept 2020

Abstract excerpt

An effective vaccine is essential for controlling the spread of the SARS-CoV-2 virus. Here, we describe an influenza virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence in an influenza virus also possessing a mutation that reduces the affinity of hemagglutinin for its sialic acid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Influenza Virus Research Studies
Share to Respiratory viral infections research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32899480
DOI: 10.3390/v12090987

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in MicePMID 32899480Read ↗

Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in miceSemantic proximity Read ↗

Influenza viral particles harboring the SARS-CoV-2 spike RBD as a combination respiratory disease vaccineSemantic proximity Read ↗

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read ↗

A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice.Semantic proximity Read ↗

Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like BetacoronavirusesSemantic proximity Read ↗

Incorporation of Sars-Cov-2 Spike Ntd to Rbd-Based Vaccine Improves Immunity and Protection Against Viral VariantsSemantic proximity Read ↗

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesSemantic proximity Read ↗

Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopesSemantic proximity Read ↗

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variantsSemantic proximity Read ↗

Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variantsSemantic proximity Read ↗

Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related virusesSemantic proximity Read ↗

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.